Body mass index as a predictor of healthy and disease-free life expectancy between ages 50 and 75 : a multicohort study by Stenholm, S. et al.
OPEN
ORIGINAL ARTICLE
Body mass index as a predictor of healthy and disease-free life
expectancy between ages 50 and 75: a multicohort study
S Stenholm1, J Head2, V Aalto3, M Kivimäki2,3,4, I Kawachi5, M Zins6,7,8, M Goldberg6,7, LG Platts9, P Zaninotto2, LL Magnusson Hanson9,
H Westerlund9 and J Vahtera1
BACKGROUND: While many studies have shown associations between obesity and increased risk of morbidity and mortality, little
comparable information is available on how body mass index (BMI) impacts health expectancy. We examined associations of BMI
with healthy and chronic disease-free life expectancy in four European cohort studies.
METHODS: Data were drawn from repeated waves of cohort studies in England, Finland, France and Sweden. BMI was categorized
into four groups from normal weight (18.5–24.9 kg m− 2) to obesity class II (⩾35 kg m− 2). Health expectancy was estimated with
two health indicators: sub-optimal self-rated health and having a chronic disease (cardiovascular disease, cancer, respiratory disease
and diabetes). Multistate life table models were used to estimate sex-speciﬁc healthy life expectancy and chronic disease-free life
expectancy from ages 50 to 75 years for each BMI category.
RESULTS: The proportion of life spent in good perceived health between ages 50 and 75 progressively decreased with increasing
BMI from 81% in normal weight men and women to 53% in men and women with class II obesity which corresponds to an average
7-year difference in absolute terms. The proportion of life between ages 50 and 75 years without chronic diseases decreased from
62 and 65% in normal weight men and women and to 29 and 36% in men and women with class II obesity, respectively. This
corresponds to an average 9 more years without chronic diseases in normal weight men and 7 more years in normal weight
women between ages 50 and 75 years compared to class II obese men and women. No consistent differences were observed
between cohorts.
CONCLUSIONS: Excess BMI is associated with substantially shorter healthy and chronic disease-free life expectancy, suggesting
that tackling obesity would increase years lived in good health in populations.
International Journal of Obesity (2017) 41, 769–775; doi:10.1038/ijo.2017.29
INTRODUCTION
Obesity is a major global public health challenge of our times. The
prevalence of overweight and obesity has increased signiﬁcantly
over the past three decades and concerns about the health risks
associated with obesity have become nearly universal.1 Excess
adiposity is associated with an increased risk for morbidity, in
particular type 2 diabetes, coronary heart disease, heart failure and
several types of cancer2–4 as well as with elevated mortality risk.5,6
In addition, among older people, obesity carries an increased risk
of lower extremity osteoarthritis,7 and reduced functional capacity
and quality of life.8–11 The adverse effects of obesity raise the
question about corresponding losses in life spent in good health.
This issue has not been examined in detail although it has
important implications for both individuals and for societies
dealing with increasing health-care costs and care dependency.
A useful summary measure that captures both the 'quantity'
and 'quality' of life is the estimation of health expectancy. This
concept takes into account both morbidity and mortality and is
therefore useful in comparing the health of different populations
and population sub-groups.12,13 To date, there are a limited
number of studies that have examined how body mass index
(BMI) impacts health expectancy.14–21 Moreover, health indicators
used to compute health expectancy have varied across studies—
for example, single versus multiple chronic diseases,14,15,22 health-
related quality of life,16 disability17–19 or quality-adjusted years20—
which has hindered our ability to draw comparisons across
populations.
Some studies15,16 have estimated health expectancy based on
cross-sectional methods, that is, prevalence-based life tables of
health status, also known as Sullivan’s Method.23 The advantage of
using longitudinal methods, such as multistate life tables (MSLT),
in estimating health expectancy is that they take into account the
possibility of returning to a state of good health using incident
rates instead of prevalence.24 When longitudinal data on health
development are available, the incidence-based MSLT is prefer-
able because it most accurately reﬂects the impact of current
conditions (that is, disease onset, recovery, and mortality) on the
evolution of health expectancy in the target population.25
To the best of our knowledge few studies have prospectively
studied health expectancy across BMI categories. In these studies
healthy years were operationalized in terms of quality-adjusted life
years,20 years without cardiovascular disease14,22 and disability-
free years.17 None of the studies used self-rated health which is a
global measure of health status and commonly used to estimate
health expectancy. In addition, all the above-mentioned studies
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examined health expectancy for only three broad BMI categories:
normal weight, overweight and obesity. With increasing pre-
valence of severe obesity, more information is needed about
health expectancy at the extreme of BMI distribution, that is,
obesity and severe obesity, which typically associate with excess
morbidity and mortality.26
The objective of this study was to address the above-mentioned
gaps by examining health expectancy across BMI categories in
large cohorts of older men and women living in England, Finland,
France and Sweden. In each of the cohorts health expectancy was
deﬁned using two different health indicators: sub-optimal self-
rated health and having a chronic disease.
MATERIALS AND METHODS
Study population
We used data from four prospective cohort studies from England, Finland,
France and Sweden to calculate partial life expectancy (LE) and health
expectancies between the ages of 50 and 75. In all cohorts, people aged 50
years or older with valid data on health and BMI were included from the
ﬁrst observation. We limited our calculation of partial LE to an upper age of
75 as not all cohorts had participants aged 75 and older and this choice
allowed us to have comparable time frames for each cohort.
The English data are from the ﬁrst six waves (2002–2003 to 2012–2013)
of the English Longitudinal Study of Ageing (ELSA), an open-access,
nationally representative biennial longitudinal survey of those aged 50 and
over living in private households in England who had previously taken part
in the Health Survey for England in 1998, 1999 or 2001 (wave 0).27 We
included 7225 participants aged 50–75 years at baseline who had valid
information on objectively measured BMI collected during the home visit
at either wave 0 or wave 2.
The Finnish data are from ﬁve waves of the Finnish Public Sector study
(FPS). The FPS, established in 1997/1998, comprises all 151 901 employees
with ⩾ 6 month job contract in any year from 1991/2000 to 2005 in 10
towns and 5 hospital districts in Finland. Survey data has been collected by
repeated surveys at 4-year intervals on all 103 866 cohort members, who
were working in the participating organizations during the surveys in the
years 1997/1998, 2000/2001, 2004/2005, 2008/2009 and/or 2012/2013 or
had retired or left the organizations after the 2000/2001 survey. For the
analysis we used data from 42 702 participants aged 50–75 years at the
ﬁrst wave for which valid data on BMI was available.
The French data are from the GAZEL Cohort Study, established in 1989
among Électricité de France-Gaz de France (EDF-GDF) workers, the French
national utility company, with annual waves of data collection up to 2014.
At inception in 1989, the GAZEL Cohort Study contained 20 625 volunteers
(15 011 men and 5614 women) working at EDF-GDF who were then aged
from 35 to 50 years.28 We included 14 967 participants who had valid
information on BMI measured in 1996 and who were aged 50–57 years at
the ﬁrst wave.
Data for Sweden came from ﬁve waves of the Swedish Longitudinal
Occupational Survey of Health (SLOSH).29 The ﬁrst wave of SLOSH in 2006
was a postal questionnaire follow-up of all respondents to the 2003
Swedish Work Environment Survey (SWES), a cross-sectional, biennial
survey of a random stratiﬁed sample of those gainfully employed people
aged 16–64 years. At wave 2 in 2008, the sample was increased by adding
the respondents from the 2005 SWES yielding an overall sample of
n= 18 915 women and men originally representative of the working
population in Sweden in 2003 and 2005. These people were then re-
surveyed in 2010, 2012 and 2014. In total, 77% responded at least once.
The analytic sample in the present study comprised the 8048 participants
who had responded to at least one SLOSH wave and who were aged 50–
75 years at the ﬁrst wave for which valid data on BMI was recorded.
In all cohorts, participants gave their informed consent to take part.
Ethical approval was given in each of the countries from relevant ethical
committees/boards.
Measurement of BMI
BMI was calculated using self-reported body weight and height in FPS,
GAZEL and SLOSH. In ELSA, body weight and height were measured by a
study nurse in the participants’ homes. Obesity was categorized according
to World Health Organization cutoff criteria as (1) underweight (BMI
o18.5 kg m− 2), (2) normal weight (18.5–24.9 kg m− 2), (3) overweight (25–
29.9 kg m− 2), (4) obese class I (30–34.9 kg m− 2) and (5) obese class II
(⩾35 kg m− 2).30 Because the proportion of underweight men and women
in each cohort was less than 1% with the exception of GAZEL women (3%),
the underweight people were excluded from the analyses.
Outcome measures
In each study cohort, we deﬁned two health expectancy outcomes: (1)
healthy LE using self-rated health and (2) chronic disease-free LE based on
the occurrence of chronic diseases. In addition, we took mortality into
account.
Self-rated health. All participants were asked about their health status at
each wave. Responses were categorized into good and sub-optimal health.
In ELSA, FPS and SLOSH participants were asked to rate their general
health on a ﬁve-point Likert scale, which was dichotomized by categorizing
response scores 1–2 as good health and scores 3–5 as sub-optimal health.
GAZEL used an 8-point Likert scale (1 = very good, 8 = very poor), which
was dichotomized by categorizing response scores 1–4 as good health and
scores 5–8 as sub-optimal health, as previously validated.31 Health
expectancy based on self-rated health is labeled hereafter as healthy LE.
Chronic diseases. Presence of the following chronic diseases was
ascertained in each study by asking ‘has a doctor ever told you that you
have …’:1 heart disease (heart attack, coronary heart disease, angina,
congestive heart failure, or other heart problems),2 stroke (stroke or
transient ischemic attack),3 chronic lung disease (chronic bronchitis or
emphysema or asthma),4 cancer (cancer or a malignant tumor of any kind
except skin cancer) and5 diabetes (diabetes or high blood sugar).
Individuals were deﬁned as having a chronic disease if they reported
one or more of these conditions. The presence of chronic diseases at
baseline (ﬁrst observation included in analysis) included any chronic
diseases reported before the age of 50 from available information on
respondents. Health expectancy based on chronic diseases is hereafter
labeled as chronic disease-free LE.
Mortality was ascertained from linked register data for each study cohort
with follow-up censored on 31 December of the year in which data
collection last took place for each study cohort.
Statistical analyses
Characteristics of the participating cohorts are presented at the ﬁrst
observation point, which refers to the date each participant was included
in the dataset.
We applied multistate models to longitudinal data to obtain transition
probabilities between health states. Discrete-time multistate life table
models were used to estimate partial LE and healthy LE and chronic
disease-free LE between the ages of 50 and 75 years (in total 26 years). For
both outcome measures, three health states were deﬁned: healthy,
unhealthy and dead. For healthy LE, there were four possible transitions
between the health states, namely: healthy to sub-optimal health (onset),
sub-optimal health to healthy (recovery), healthy to dead, sub-optimal
health to dead. For chronic disease-free LE, there were only three possible
transitions as, by deﬁnition, recovery was not possible.
For each study cohort, age-speciﬁc transition probabilities by sex and
BMI were estimated from multinomial logistic models with age (in years),
sex and socioeconomic position as covariates. Partial LE, healthy LE and
chronic disease-free LE from ages 50–75 years were then calculated based
on these estimated transition probabilities using a stochastic (micro-
simulation) approach.32 For each study, individual trajectories for a
simulated cohort of 100 000 persons were generated with distributions
of covariates at the starting point based on the observed study-speciﬁc
prevalence by ﬁve year age group, sex, socioeconomic position and BMI.
Partial LE, healthy LE and chronic disease-free LE from age 50 to 75 were
then calculated as the average from these trajectories for BMI and sex.
Computation of 95% conﬁdence intervals (CI) (from 2.5th and 97.5th
percentiles) for these multistate life table estimates was performed using a
bootstrap method with 500 replicates for the whole analysis process
(multinomial analysis and simulation steps). As BMI-related transitions to
poor health and death may differ by sex, we repeated analyses including
interactions between sex and BMI in the multinomial logistic models.
Finally, since tobacco smoking is associated with increased risk of mortality
and morbidity33,34 and it is also typically associated with lower weight,35
we conducted sensitivity analyses among never smokers using a bootstrap
method with 50 replicates.
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All analyses were conducted in SAS 9.2 using the SPACE (Stochastic
Population Analysis of Complex Events) program.36,37 This program uses
the stochastic (that is, microsimulation) approach to estimate the healthy
LE as opposed to another well-known program, IMaCh (Interpolation of
Markov Chains) which uses a deterministic approach.38
RESULTS
Characteristics of the study cohorts for men and women at the
time of ﬁrst observation are shown in Table 1. Prevalence of
obesity (BMI⩾ 30 kg m− 2) varied across cohorts. Obesity was most
common among English men (24%) and women (29%) in ELSA,
followed by Finnish and Swedish men and women being around
15% in FPS and SLOSH. Obesity was rare among French men and
women in GAZEL cohort (7%). At baseline, there were also some
differences in the prevalence of sub-optimal self-rated health
across study cohorts ranging among men from 19% (GAZEL) to
37% (FPS) and among women from 20% (SLOSH) to 34% (FPS).
Chronic disease was most common among ELSA men (34%) and
women (31%) and least common in SLOSH men (22%) and
women (17%).
Partial LE between ages 50 and years 75 (in total 26 years) for
men was 23.7 years in ELSA, 24.1 years in FPS, 24.5 years in GAZEL
and 25.2 years in SLOSH. The corresponding ﬁgures for women
were 24.4 years for ELSA, 24.9 years for FPS, 25.0 years for GAZEL
and 25.5 years for SLOSH. On the basis of the most recent national
records, the total LE at age 50 for men in England was 31.3, in
Finland 30.3, in France 30.8 and in Sweden 32.0 years.
Corresponding ﬁgures for women were 34.4 for England, 35.0
for Finland, 36.2 for France and 35.1 for Sweden. Thus, the
differences in country-level differences in total LE at age 50 were
consistent with the cohort-speciﬁc partial LEs that we observed.
Table 2 shows estimates of partial LE between ages 50 and 75
years, divided into healthy and unhealthy LE based on self-
reported health and BMI. The partial LE was highest among
normal weight and overweight participants and lowest among
obese class II participants across the study cohorts. There was a
gradient toward shorter healthy LE with increasing BMI. Normal
weight men and women could expect to live on average 81% of
their life between 50 and 75 years in good health. The
corresponding ﬁgure was only 64% among obese class I and
53% among obese class II participants (Figure 1). In terms of
absolute number of years, normal weight participants from the
ELSA, GAZEL and SLOSH cohorts could expect to live on average 3
and 7 years longer in good health compared to those in obesity
classes I and II, respectively. In the FPS cohort, the gradient from
normal weight to obese class II was slightly larger than in other
cohorts, the corresponding differences in healthy years being 6
and 10 years, respectively.
Results for the partial LE, chronic disease-free LE and LE with
chronic diseases are shown in Table 3. The proportion of years
without chronic diseases between ages 50–75 years ranged from
60 (ELSA and FPS) to 65% (SLOSH) in normal weight men and from
59 (FPS) to 73% (SLOSH) in normal weight women (Figure 2). In
ELSA the difference between normal weight and obesity classes I
and II was 2 and 5 years in men and 2 and 6 years in women,
respectively. In all other cohorts, the loss in healthy years among
obese classes I and II participants compared to normal weight
participants was much larger, 5 and 10 years in men and 5 and 8
years in women, respectively.
To take into account the potential confounding by smoking, we
repeated our analyses by including only never smokers at
baseline. Healthy LE and chronic disease-free LE were on average
one year longer across all BMI categories in all cohorts and thus
the gradient in decreasing healthy LE and chronic disease-free LE
with increasing BMI remained similar as in the total population
(Supplementary eTables 1 and 2).
Finally, we tested the sex × BMI interaction in multinomial
logistic models. In most cases, this did not signiﬁcantly improve
model ﬁt. However, the interaction was signiﬁcant for self-rated
health in GAZEL where the increased risk of remaining in poor
Table 1. Characteristics of the study cohorts at the time of ﬁrst observationa
ELSA FPS GAZEL SLOSH
Men Women Men Women Men Women Men Women
Sample size 4071 4733 8343 34 173 11 098 3833 3663 4326
Age (mean, s.d.) 61.5 (7.2) 61.4 (7.3) 53.6 (3.2) 53.2 (2.9) 52.0 (2.2) 51.4 (2.0) 58.0 (5.8) 57.3 (5.7)
Socioeconomic position (%)
High grade 36.5 24.9 42 27 32.8 9.2 22.8 17.1
Middle grade 19.8 27.3 24.1 56.4 55.3 67.7 36.5 51.7
Low grade 43.8 47.8 33.9 16.6 11.8 23.1 40.7 31.1
Sub-optimal self-rated health (%) 25.2 23.8 37.3 34.1 19.2 23.5 23.6 20.3
Chronic disease (%)b 34.4 31.3 25.5 26 23.1 25.3 21.7 17.2
Body mass index (%)
Underweight (o18.5 kg m− 2) 0.3 0.9 0.2 0.8 0.3 2.9 0.2 0.9
Normal weight (18.5–24.9 kg m− 2) 23.5 32 35.4 51.1 44.1 69.8 33.6 52.5
Overweight (25–29.9 kg m− 2) 52.3 38.3 49 33.7 48.3 20.4 52 34.2
Obese class I (30–34.9 kg m− 2) 19.2 19.3 12.4 11 6.5 5.5 12 9.7
Obese class II (⩾35 kg m− 2) 4.8 9.6 3 3.4 0.7 1.6 2.2 2.7
Smoking
Never smoking, % 27.4 43.5 50.7 67.7 35.2 67.9 52.7 50.4
Former smoking, % 53.5 36 27.7 17 35.3 11.8 32.1 31.3
Current smoking, % 19.1 20.5 21.6 15.3 29.6 20.3 15.3 18.3
aThe ﬁrst observation point refers to the date each participant was included in the dataset. bPresence of chronic diseases includes illness reported at or before
the ﬁrst observation point.
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Table 2. Partial life expectancy, healthy life expectancy and unhealthy life expectancy based on self-reported health between ages 50 and 75 years
by body mass index in each study cohort
Life expectancy 95% CI Healthy life expectancy 95% CI Unhealthy life expectancy 95% CI
Men
ELSA
Normal weight 23.83 23.46 24.05 18.98 18.37 19.64 4.86 4.26 5.24
Overweight 24.01 23.83 24.25 18.68 18.3 19.22 5.32 4.92 5.7
Obese class I 23.45 23.21 23.82 16.37 15.8 17.12 7.08 6.39 7.67
Obese class II 23.17 22.36 23.48 13.07 11.54 13.93 10.1 9.07 11.34
FPS
Normal weight 24.26 24.12 24.58 18.23 17.82 18.56 6.03 5.81 6.52
Overweight 24.26 24.03 24.47 15.21 14.73 15.55 9.05 8.71 9.51
Obese class I 23.53 23.22 24.04 11.43 11.05 12.54 12.1 11.29 12.55
Obese class II 22.76 21.8 23.51 7.97 6.57 8.79 14.79 13.7 16.16
GAZEL
Normal weight 24.56 24.43 24.72 21.13 20.9 21.34 3.43 3.29 3.6
Overweight 24.57 24.45 24.71 20.43 20.23 20.62 4.14 3.97 4.32
Obese class I 23.69 23.22 24.16 18.16 17.61 18.84 5.53 5.09 5.99
Obese class II 23.35 21.65 24.54 14.65 12.93 16.63 8.7 6.94 9.81
SLOSH
Normal weight 25.26 24.81 25.53 20.91 20.25 21.55 4.35 3.75 4.85
Overweight 25.23 24.94 25.49 19.21 18.6 19.87 6.03 5.45 6.47
Obese class I 25.7 25.29 26 15.96 14.79 17.07 9.74 8.66 10.98
Obese class II 24.22 21.99 26 13.72 10.99 16.32 10.5 7.89 12.96
Women
ELSA
Normal weight 24.59 24.43 24.8 20.08 19.72 20.62 4.51 4.12 4.81
Overweight 24.71 24.56 24.87 19.36 18.75 19.79 5.36 5 5.89
Obese class I 24.35 24.14 24.56 17.19 16.5 17.74 7.16 6.71 7.79
Obese class II 23.87 23.51 24.31 13.06 11.86 14.15 10.81 9.91 11.96
FPS
Normal weight 25.05 24.95 25.14 18.41 18.28 18.69 6.63 6.38 6.78
Overweight 25.01 24.91 25.13 15.46 15.24 15.77 9.54 9.26 9.79
Obese class I 24.72 24.47 24.87 12.47 11.85 12.72 12.25 11.93 12.85
Obese class II 24.12 23.7 24.62 9.06 8.23 9.93 15.05 14.18 16
GAZEL
Normal weight 25.07 24.85 25.16 20.54 20.26 20.81 4.53 4.24 4.71
Overweight 24.92 24.79 25.21 19.63 19.3 20.09 5.3 4.98 5.67
Obese class I 24.58 24.11 24.93 17.64 16.87 18.43 6.94 6.3 7.56
Obese class II 24.18 23.01 25.13 13.94 12.32 15.73 10.24 8.39 11.79
SLOSH
Normal weight 25.45 25.21 25.68 21.67 21.13 22.12 3.78 3.43 4.35
Overweight 25.45 25.14 25.7 19.9 19.27 20.43 5.54 5.07 6.11
Obese class I 25.74 25.3 26 17.02 15.51 18.36 8.72 7.59 10.23
Obese class II 24.84 23.73 26 15.83 13.71 18.16 9 6.81 11.21
Abbreviation: CI, conﬁdence interval.
Figure 1. Proportion (95% CI) of life spent in good health between ages 50 and 75 by body mass index in each study cohort. (a) Men,
(b) Women.
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Table 3. Partial life expectancy, chronic disease-free life expectancy and life expectancy with chronic diseases between ages 50 and 75 years by body
mass index in each study cohort
Life expectancy 95% CI Chronic disease-free
life expectancy
95% CI Life expectancy with
chronic diseases
95% CI
Men
ELSA
Normal weight 23.62 23.24 23.89 14.2 12.93 15.54 9.42 8.08 10.63
Overweight 23.91 23.7 24.25 14.12 13.1 15.46 9.79 8.56 10.79
Obese class I 23.53 23.06 23.78 12.44 11.06 13.89 11.08 9.67 12.38
Obese class II 23 22.39 23.68 8.88 6.59 10.88 14.12 12.3 16.34
FPS
Normal weight 24.16 23.98 24.44 14.44 13.97 14.96 9.72 9.23 10.28
Overweight 24.25 24 24.41 12.66 12.03 12.98 11.59 11.24 12.2
Obese class I 23.55 23.11 24.03 9.33 8.2 9.65 14.22 13.83 15.64
Obese class II 22.23 21.62 23.52 5.99 5.15 7.25 16.24 15.11 17.85
GAZEL
Normal weight 24.53 24.4 24.7 15.52 15.15 15.83 9.01 8.73 9.41
Overweight 24.58 24.41 24.7 13.97 13.69 14.37 10.61 10.18 10.87
Obese class I 23.78 23.29 24.2 10.78 10.1 11.86 13 11.79 13.7
Obese class II 23.37 21.65 24.38 5.32 3.81 7.43 18.04 15.22 19.65
SLOSH
Normal weight 25.19 24.74 25.53 16.35 15.26 17.57 8.85 7.56 9.95
Overweight 25.19 24.92 25.5 14.42 13.5 15.31 10.77 9.86 11.72
Obese class I 25.66 25.27 26 9.86 8.46 11.47 15.8 14.29 17.2
Obese class II 24.33 21.31 26 6.53 4.79 10.28 17.79 14.12 20.24
Women
ELSA
Normal weight 24.48 24.27 24.69 15.81 14.72 17.09 8.67 7.43 9.66
Overweight 24.62 24.47 24.83 15 13.88 16.65 9.63 8.09 10.82
Obese class I 24.38 24.09 24.58 13.85 12.18 15.45 10.53 8.98 12.1
Obese class II 23.95 23.49 24.32 9.5 7.84 11.74 14.45 12.06 15.96
FPS
Normal weight 24.98 24.92 25.1 14.67 14.39 14.95 10.32 10.02 10.62
Overweight 24.94 24.89 25.12 12.73 12.39 13.04 12.2 11.97 12.62
Obese class I 24.54 24.43 24.86 10.02 9.56 10.48 14.52 14.14 15.15
Obese class II 24.17 23.62 24.58 7.29 6.69 8.29 16.88 15.78 17.53
GAZEL
Normal weight 25.06 24.88 25.22 15.8 15.38 16.35 9.26 8.69 9.64
Overweight 25 24.8 25.19 13.96 13.1 14.73 11.04 10.37 11.88
Obese class I 24.33 24.02 24.9 11.16 10.13 12.51 13.18 12.02 14.26
Obese class II 24.35 22.86 24.99 8.37 5.52 10.65 15.98 13.15 18.84
SLOSH
Normal weight 25.46 25.22 25.65 18.5 17.6 19.14 6.96 6.27 7.78
Overweight 25.42 25.18 25.69 15.45 14.35 16.37 9.97 9.02 11.05
Obese class I 25.82 25.48 26 11.39 9.87 12.93 14.43 12.74 15.99
Obese class II 24.73 23.28 26 10.27 7.34 13.28 14.45 11.75 17.72
Abbreviation: CI, conﬁdence interval.
Figure 2. Proportion (95% CI) of life spent without chronic disease between ages 50 and 75 by body mass index in each study cohort. (a) Men,
(b) Women.
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health in the class II obesity was more marked in women than in
men (P= 0.013).
DISCUSSION
This study examined how BMI status was associated with healthy
and chronic disease-free LE in men and women in four different
cohorts from the England, Finland, France and Sweden. Our
ﬁndings showed clear differences between BMI categories
indicating that normal weight and overweight people could
expect to live longest and normal weight people would spend
about 81% and overweight 76% of those years in good health.
Although the LE among class I and class II obese was on average
only one year less than that among the normal weight, class II
obese people could expect to live 6–7 fewer years in good health
and 7–9 fewer years without chronic diseases compared to those
with normal weight.
To our knowledge, this is the ﬁrst prospective study to provide
health expectancy estimates for both self-rated health and chronic
diseases across BMI categories by applying multistate models to
longitudinal data to obtain transition probabilities between health
states. By performing detailed inspection of the WHO’s BMI
classiﬁcation and splitting obesity category (BMI⩾ 30 kg m− 2) into
two obesity subcategories (class I and II obese) we demonstrated
important variation in LE and health expectancies. Although there
was only 0.5 year difference in LE from ages 50 to 75 years
between class I and class II obese, the difference in healthy and
chronic disease-free LE was about 4 years. Similar loss of health
expectancy at higher obesity classes was also observed in a recent
cross-sectional analysis.16 The heterogeneity within the group of
obese people was also observed in the European Community
Household Panel study in which disability-free LE across BMI
categories was evaluated.17
In contrast to some previous studies which have reported
longer LE among overweight than normal weight adults,14,16 we
did not observe marked LE difference between these groups. In a
recent meta-analysis overweight was associated with lower all-
cause mortality among subjects aged ⩾ 65 years old,5 but in the
current study the participants were on average younger than 60
years at baseline. This difference in results may be explained by a
greater potential for confounding by illness in older age groups.
With advancing age the prevalence of many diseases increase
which may lead to weight loss, thus making normal weight appear
disadvantageous in terms of LE at older ages. Despite similar LE
between normal weight and overweight groups, our analysis
showed that normal weight participants had more healthy years
and years without chronic diseases than overweight participants
even after taking into account smoking status. Similar ﬁndings
related to beneﬁcial role of normal weight have been reported in
terms of LE without cardiovascular disease14,22 and disability.17
The ﬁndings of the study are highly relevant because together
with an increase in obesity prevalence, the average number of
years of life have continuously increased with no apparent plateau
in Western countries.39,40 The main question is how healthily the
gained years of life will be spent. We showed consistent results
across four different European countries suggesting that the
obesity epidemic is likely to considerably decrease the proportion
of life that is spent in good health. This has important implications
for individuals and societies.41
The current study has a number of strengths. The major one is
that our data are based on large prospective cohorts from four
European countries, with multiple measurements of self-rated
health and chronic diseases over time, long follow-up and high-
quality harmonized data. In addition, we used microsimulation to
estimate healthy LE and chronic disease-free LE which provides
internally consistent results for each cohort.
The study also has a number of limitations that needs to be
considered when interpreting the ﬁndings. First, although all
cohorts showed consistent patterns of decreasing years of good
health from normal weight to class II obese, the absolute
difference in the years varied slightly across cohorts and by the
health indicator. Despite careful harmonization there was some
heterogeneity in the deﬁnitions of health and chronic diseases
between cohort studies and the cohorts were also different in
terms of representativeness and age.42 Indeed, ELSA is the only
study including a national representative sample of older
individuals, whereas FPS, GAZEL and SLOSH are occupational
cohorts including individuals initially healthy enough to be in the
labor force. However, the fact that the main ﬁndings were similar
across different source populations suggests that the associations
observed are robust and not restricted to some population
segments. Second, BMI was based on objectively measured body
weight and height only in ELSA. All other cohorts relied on self-
reported information, suggesting that the data could be subject to
potential measurement errors which hampers comparisons
between cohorts.
Previous studies have shown that overweight and obese
persons tend to underreport their weight which may lead to
underestimation of BMI and potential misclassiﬁcation of some
individuals into incorrect BMI categories.43,44 Despite to this
potential misclassiﬁcation towards lower BMI categories in other
cohorts than ELSA, the data from WHO’s database suggests that
adult obesity prevalence is highest in England (24% in men and
26% in women), followed by Finland (21 and 19%), Sweden (13
and 12%) and France (9 and 8%),45 which corresponds with BMI
distribution in our study cohorts. In addition, previous studies
have shown that health risk estimates associated with BMI values
are very similar, whether based on self-report or measured BMI
values.46 Thus, it is unlikely that different ways of obtaining BMI
data have markedly inﬂuenced on our main ﬁndings. Third, the
number of underweight participants was too low to derive reliable
estimates of its effect on healthy and chronic disease-free LE and
thus this group was excluded from our analyses and should be
examined in future studies with larger sample sizes. Finally, our life
expectancy analyses were conditional on reaching age of 50 and
truncated at age 75. Future studies are needed to investigate the
association of BMI and healthy and chronic disease-free LE starting
at younger ages and extending follow-up beyond the age of
75 years.
In conclusion, data from four European countries show that
obese and severely obese people can expect to live much higher
proportion of their life in sub-optimal health and with chronic
diseases compared to normal weight people. Given the large
impact of obesity on the burden of ill-health and the general
increase in life expectancy, slowing down the obesity epidemic at
the population level is essential to increase the time spent in good
health.
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